Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials

• Published in: The American journal of clinical nutrition 2010-02, Vol.91 (2), p.480-486
• Main Authors: LI, Shao-Hua, LIU, Xu-Xia, BAI, Yong-Yi, WANG, Xiao-Jian, KAI SUN, CHEN, Jing-Zhou, HUI, Ru-Tai
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Cardiovascular Diseases - prevention & control; Clinical trials; Dietary Supplements; Effects; Endothelium, Vascular - drug effects; Feeding. Feeding behavior; Female; Fundamental and applied biological sciences. Psychology; Humans; Isoflavones - administration & dosage; Menopause; Meta-analysis; Middle Aged; Placebos; Postmenopause - drug effects; Randomized Controlled Trials as Topic; Regression analysis; Studies; Vasodilation - drug effects; Vertebrates: anatomy and physiology, studies on body, several organs or systems
• ISSN: 0002-9165; 1938-3207
• DOI: 10.3945/ajcn.2009.28203

The effect of isoflavone on endothelial function in postmenopausal women is controversial. The objective of this study was to evaluate the effect of oral isoflavone supplementation on endothelial function, as measured by flow-mediated dilation (FMD), in postmenopausal women. A meta-analysis of randomized placebo-controlled trials was conducted to evaluate the effect of oral isoflavone supplementation on endothelial function in postmenopausal women. Trials were searched in PubMed, Embase, the Cochrane Library database, and reviews and reference lists of relevant articles. Summary estimates of weighted mean differences (WMDs) and 95% CIs were obtained by using random-effects models. Meta-regression and subgroup analyses were performed to identify the source of heterogeneity. A total of 9 trials were reviewed in the present meta-analysis. Overall, the results of the 9 trials showed that isoflavone significantly increased FMD (WMD: 1.75%; 95% CI: 0.83%, 2.67%; P = 0.0002). Meta-regression analysis indicated that the age-adjusted baseline FMD was inversely related to effect size. Subgroup analysis showed that oral supplementation of isoflavone had no influence on FMD if the age-adjusted baseline FMD was > or = 5.2% (4 trials; WMD: 0.24%; 95% CI: -0.94%, 1.42%; P = 0.69). This improvement seemed to be significant when the age-adjusted baseline FMD levels were